



FORM 13  
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER  
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : Mr. R. Vanlalruata, Assistant Director (F and D)  
ASSISTANT DIRECTOR(F&D)  
OFFICE OF CHIEF MEDICAL OFFICER, AIZAWL,  
MIZORAM, PIN-769017
2. Serial No. and date of Inspector's memorandum : MZ/24/A E/05 , 15-OCT-2024
3. Number of Sample : NIL
4. Date of receipt : 01-NOV-2024
5. Names of drugs purporting to be contained in the sample : Montelukast Sodium & Levocetirizine Dihydrochloride  
Tablets (Levomont)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-26/0080	GUW/LS/2025-26/85	T-3438	Feb-2024 Jan-2026	NA	Jackson Laboratories Pvt.Ltd, 22-24, Majitha Road, Bye Pass, Amritsar-143 001(India)

6. Condition of seals on : Seals were intact & identical to the  
[the packet or on portion of sample or container] specimen impression of the seal received  
from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied : Please see below  
Date of Testing : From 20-Mar-2025 To 09-Apr-2025

COMPOSITION : Each film coated tablet contains:  
Montelukast Sodium IP eq. to Montelukast 10 mg  
Levocetirizine Dihydrochloride IP 5 mg

**Protocol Applied : I.P. 2022**

Sr No.	Test Name	Result	Limits
1	Description	White, round, bi-convex, scored on one surface, film coated tablets, in blister packing.	NA
2	Identification	Gives positive test for Montelukast Sodium & Levocetirizine Dihydrochloride.	NA
3	Average weight	0.2013 g	NA

**Assay**

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Montelukast Sodium eq. to Montelukast	10.14 mg/Tablet	10 mg/Tablet	101.4	90 % to 110 %	I.P. 2022

2	Levocetirizine Dihydrochloride	4.71 mg/Tablet	5 mg/Tablet	94.2	90 % to 110 %	I.P. 2022
---	-----------------------------------	----------------	----------------	------	---------------	-----------

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

**The sample conform to claim as per I.P. 2022 in respect of test performed.**

**Date:** 16-APR-2025

**GOVERNMENT ANALYST**

*Rinku Kalita*  
Rinku Kalita  
Government Analyst  
R.D.T.L., Guwahati-22

-----END OF REPORT-----

